Insitro is a drug discovery and development startup that utilizes machine learning and biology to transform drug discovery.
Insitro is an operator of a data-driven drug discovery and development company that utilizes machine learning and high-throughput biology to transform the way that drugs are discovered and delivered to patients.The company uses state-of-the-art technologies from bioengineering enabling it to generate high-throughput, functional genomic data sets and aligning them with patient data via novel machine learning methods, thereby building predictive models that can accelerate target selection and the design and development of effective therapeutics.In 2018, Daphne Koller established Insitro in South San Francisco, California..
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Mar 15, 2021 | Series C | $400M | 1 | — | — | Detail |
May 26, 2020 | Series B | $143M | 1 | — | — | Detail |
Apr 16, 2019 | Series A | $100M | 1 | — | — | Detail |
May 2, 2018 | Series A | $100M | 2 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
ARCH Venture Partners | — | Series C |
Verily | — | Series A |